Indevus/Pliva Sanctura clears FDA
Executive Summary
Indevus/Pliva's Sanctura (trospium) clears FDA May 28 for treatment of overactive bladder. Product will be launched in third quarter. Sanctura is first new molecular entity approved for overactive bladder since Pharmacia's Detrol (tolterodine) in 1998 [Editor's Note: More coverage of the Sanctura approval appears in 1"The Pink Sheet" DAILY. Visit our website, www.ThePinkSheetDAILY.com, to sign up for a free trial.]....
You may also be interested in...
Indevus/Pliva Sanctura Will Enter Overactive Bladder Market In Third Quarter
Indevus/Pliva's Sanctura will enter the overactive bladder market during the third quarter
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.